Induction Therapy for Acute Myelogenous Leukemia in Patients Over 60 Years with Intermediate-Dose Cytosine Arabinoside, Mitoxantrone and Etoposide

References

• Phillips G. L., Reece D. E., Shepherd J. D., Barnett M. J., Brown R. A., Frei-Lahr D. A., Klingemann H. G., Boswell B. J., Spinelli J. J., Herzig R. H., Herzig G. P. High-dose cytarabine and daunorubicin induction and postremission chemotherapy for the treatment of acute myelogenous leukemia in adults. Blood 1991; 77: 1429–35
   PubMed Web of Science ®Google Scholar
• Wolff S. N., Herzig R. H., Fay J. W., Phillips G. L., Lazarus H. M., Flexner J. M., Stein R. S., Greer J. P., Cooper B., Herzig G. P. High-dose cytarabine and daunorubicin as consolidation therapy for acute myeloid leukemia in first remission: Long-term follow-up and results. J. Clin. Oncol. 1989; 7: 1260–7
   PubMed Web of Science ®Google Scholar
• Lazarus H. M., Vogler W. R., Burns C. P., Winton E. F. High-dose cytosine arabinoside and daunorubicin as primary therapy in elderly patients with acute myelogenous leukemia. A phase I-II study of the Southeastern Cancer Study Group. Cancer 1989; 63: 1055–9
   PubMed Web of Science ®Google Scholar
• Preisler H. D., Raza A., Barcos M., Azarnia N., Larson R., Walker I., Browman M., Grunwald H., D'Arrigo P., Doeblin T., Bloom M., Stein A., Logue G., Goldberg J., Kirshner J., Gottlieb A., Bennett J. High-dose cytosine arabinoside as the initial treatment of poor-risk patients with acute nonlymphocytic leukemia: A Leukemia Intergroup study. J. Clin. Oncol. 1987; 5: 75–82
   PubMed Web of Science ®Google Scholar
• Brincker H. Estimate of overall treatment results in acute nonlymphocytic leukemia based on age-specific rates of incidence and of complete remission. Cancer Treat. Rep. 1985; 69: 5–11
   PubMedGoogle Scholar
• Lowenberg B., Zittoun R., Kerkhofs H., Jehn U., Abels J., Debusscher L., Cauchie C., Peetermans M., Solbu G., Suciu S., Stryckmans P. On the value of intensive remission-induction chemotherapy in elderly patients of 65 + years with acute myeloid leukemia: A randomized phase III study of the European Organization for Research and Treatment of Cancer Leukemia Group. J. Clin. Oncol. 1989; 7: 1268–74
   PubMed Web of Science ®Google Scholar
• Reiffers J., Raynal F., Broustet A. Acute myeloblastic leukemia in elderly patients: Treatment and prognostic factors. Cancer 1980; 45: 2816–20
   PubMed Web of Science ®Google Scholar
• Foon K. A., Zighelboim J., Yale C., Gale R. P. Intensive chemotherapy is the treatment of choice for elderly patients with acute myelogenous leukemia. Blood 1981; 58: 467–70
   PubMed Web of Science ®Google Scholar
• Estey E., Keating M. J., Plunkett W., McCredie K. B., Freireich E. J. Continuous infusion high-dose cytosine arabinoside without anthracyclines as induction and intensification therapy in adults under age 50 with newly diagnosed acute myelogenous leukemia. Semin. Oncol. 1987; 14(Suppl. 1)58–63
   PubMedGoogle Scholar
• Arlin Z. A., Silver R., Cassileth P., Armentrout S., Gams R., Daghestani A., Coleman M., Schoch I., Dukart G. Phase I-II trial of mitoxantrone in acute leukemia. Cancer Treat. Rep. 1985; 69: 61–4
   PubMedGoogle Scholar
• Bishop J. F., Lowenthal R. M., Joshua D., Matthews J. P., Todd D., Cobcroft R., Whiteside M. G., Kronenberg H., Ma D., Dodds A., Herrmann R., Szer J., Wolf M. M., Young G. Etoposide in acute nonlymphocytic leukemia. Blood 1990; 75: 27–32
   PubMed Web of Science ®Google Scholar
• Cheson B. D., Cassileth P. A., Head D. R., Schiffer C. A., Bennett J. M., Bloomfield C. D., Brunning R., Gale R. P., Grever M. R., Keating M. J., Sawitsky A., Stass S., Weinstein H., Woods W. G. Report of the National Cancer Institute-sponsored workshop on definitions of diagnosis and response in acute myeloid leukemia. J. Clin. Oncol. 1990; 8: 813–9
   PubMed Web of Science ®Google Scholar
• Kaplan E. L., Meier P. Nonparametric estimation from incomplete observations. J. Am. Stat. Assoc. 1958; 53: 457–81
   Web of Science ®Google Scholar
• Miller A. B., Hoogstraten B., Staquet M., Winkler A. Reporting results of cancer treatment. Cancer 1981; 47: 207–14
   PubMed Web of Science ®Google Scholar
• Champlin R. E., Gajewski J. L., Golde D. W. Treatment of acute myelogenous leukemia in the elderly. Semin. Oncol. 1989; 16: 51–6
   PubMed Web of Science ®Google Scholar
• Copplestone J. A., Prentice A. G. Acute myeloblastic leukaemia in the elderly. Leuk. Res. 1988; 12: 617–25
   PubMed Web of Science ®Google Scholar
• Copplestone J. A., Smith A. G., Osmond C., Oscier D. G., Hamblin T. J. Treatment of acute myeloid leukemia in the elderly: A clinical dilemma. Hematol. Oncol. 1989; 7: 53–9
   PubMed Web of Science ®Google Scholar
• Sebban C., Archimbaud E., Coiffier B., Guyotat D., Treille-Ritouet D., Maupas J., Fiere D. Treatment of acute myeloid leukemia in elderly patients: A retrospective study. Cancer 1988; 61: 227–31
   PubMed Web of Science ®Google Scholar
• Tucker J., Thomas A. E., Gregory W. M., Ganesan T. S., Malik S. T. A., Amess J. A. L., Lim J., Willis L., Rohatiner A. Z. S., Lister T. A. Acute myeloid leukemia in elderly adults. Hematol. Oncol. 1990; 8: 13–21
   PubMed Web of Science ®Google Scholar
• Kahn S. B., Begg C. B., Mazza J. J., Bennett J. M., Bonner H., Glick J. H. Full dose versus attenuated dose daunorubicin, cytosine arabinoside, and 6-thioguanine in the treatment of cute nonlymphocytic leukemia in the elderly. J. Clin. Oncol 1984; 2: 865–70
   PubMed Web of Science ®Google Scholar
• Tilly H., Castaigne S., Bordessoule D., Casassus P., Le Prise P Y., Tertian G., Desablens B., Henry-Amar M., Degos L. Low-dose cytarabine versus intensive chemotherapy in the treatment of acute nonlymphocytic leukemia in the elderly. J. Clin. Oncol. 1990; 8: 272–9
   PubMed Web of Science ®Google Scholar
• Liu Yin J. A., Johnson P. R. E., Davies J. M., Flanagan N. G., Gorst D. W., Lewis M. J. Mitozantrone and cytosine arabinoside as first-line therapy in elderly patients with acute myeloid leukaemia. Br. J. Haematol. 1991; 79: 415–20
   PubMed Web of Science ®Google Scholar